- Home
- BMA vs LEGN Comparison
BMA vs LEGN Comparison
Compare BMA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- LEGN
- Stock Information
- Founded
- BMA 1966
- LEGN 2014
- Country
- BMA Argentina
- LEGN United States
- Employees
- BMA N/A
- LEGN N/A
- Industry
- BMA Commercial Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- LEGN Health Care
- Exchange
- BMA Nasdaq
- LEGN Nasdaq
- Market Cap
- BMA 4.7B
- LEGN 5.4B
- IPO Year
- BMA 2006
- LEGN 2020
- Fundamental
- Price
- BMA $65.90
- LEGN $38.96
- Analyst Decision
- BMA Hold
- LEGN Strong Buy
- Analyst Count
- BMA 3
- LEGN 12
- Target Price
- BMA $54.50
- LEGN $73.91
- AVG Volume (30 Days)
- BMA 264.1K
- LEGN 1.6M
- Earning Date
- BMA 08-21-2025
- LEGN 08-08-2025
- Dividend Yield
- BMA 5.36%
- LEGN N/A
- EPS Growth
- BMA N/A
- LEGN N/A
- EPS
- BMA N/A
- LEGN N/A
- Revenue
- BMA $2,661,558,665.00
- LEGN $728,303,000.00
- Revenue This Year
- BMA N/A
- LEGN $65.49
- Revenue Next Year
- BMA $14.62
- LEGN $53.76
- P/E Ratio
- BMA N/A
- LEGN N/A
- Revenue Growth
- BMA N/A
- LEGN 112.46
- 52 Week Low
- BMA $42.23
- LEGN $27.34
- 52 Week High
- BMA $118.42
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- BMA 34.21
- LEGN 66.26
- Support Level
- BMA $65.76
- LEGN $34.64
- Resistance Level
- BMA $72.51
- LEGN $39.88
- Average True Range (ATR)
- BMA 2.96
- LEGN 1.46
- MACD
- BMA 0.16
- LEGN 0.37
- Stochastic Oscillator
- BMA 4.52
- LEGN 87.67
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.